OA12078A - Method for administering a phosphodiesterase 4 inhibitor. - Google Patents

Method for administering a phosphodiesterase 4 inhibitor. Download PDF

Info

Publication number
OA12078A
OA12078A OA1200200126A OA1200200126A OA12078A OA 12078 A OA12078 A OA 12078A OA 1200200126 A OA1200200126 A OA 1200200126A OA 1200200126 A OA1200200126 A OA 1200200126A OA 12078 A OA12078 A OA 12078A
Authority
OA
OAPI
Prior art keywords
drug
administered
formulation
side effects
release
Prior art date
Application number
OA1200200126A
Other languages
English (en)
Inventor
Robert D Murdoch
Theodore J Torphy
Barry D Zussman
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of OA12078A publication Critical patent/OA12078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
OA1200200126A 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor. OA12078A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
OA12078A true OA12078A (en) 2003-05-28

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200126A OA12078A (en) 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor.

Country Status (29)

Country Link
US (1) US20030212112A1 (no)
EP (1) EP1225884A4 (no)
JP (1) JP2003513038A (no)
KR (1) KR20020050249A (no)
CN (1) CN1387433A (no)
AP (1) AP2002002446A0 (no)
AR (1) AR026254A1 (no)
AU (1) AU772909B2 (no)
BG (1) BG106623A (no)
BR (1) BR0015039A (no)
CA (1) CA2389293A1 (no)
CO (1) CO5271676A1 (no)
CZ (1) CZ20021443A3 (no)
DZ (1) DZ3249A1 (no)
EA (1) EA200200502A1 (no)
HK (1) HK1049105A1 (no)
HU (1) HUP0203682A3 (no)
IL (1) IL148813A0 (no)
MA (1) MA25562A1 (no)
MX (1) MXPA02004220A (no)
NO (1) NO20021937L (no)
NZ (1) NZ518002A (no)
OA (1) OA12078A (no)
PE (1) PE20011004A1 (no)
PL (1) PL355262A1 (no)
SK (1) SK7292002A3 (no)
TR (1) TR200201150T2 (no)
UY (1) UY26422A1 (no)
WO (1) WO2001032165A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ATE417628T1 (de) * 2002-05-28 2009-01-15 Nycomed Gmbh Topisch anwendbare pharmazeutische zubereitung
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
US20060239927A1 (en) * 2003-03-31 2006-10-26 Kyowa Hakko Kogyo Co., Drug for airway administration
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
RU2576033C2 (ru) * 2009-12-03 2016-02-27 Опко Хелс, Инк. Составы на основе гиперсулфатированных дисахаридов
KR102035362B1 (ko) * 2011-12-27 2019-10-22 셀진 코포레이션 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
AU1344501A (en) 2001-05-14
UY26422A1 (es) 2001-07-31
BR0015039A (pt) 2002-06-25
JP2003513038A (ja) 2003-04-08
AR026254A1 (es) 2003-02-05
NZ518002A (en) 2004-01-30
TR200201150T2 (tr) 2002-09-23
CN1387433A (zh) 2002-12-25
PE20011004A1 (es) 2001-09-28
KR20020050249A (ko) 2002-06-26
DZ3249A1 (fr) 2001-05-10
CA2389293A1 (en) 2001-05-10
MA25562A1 (fr) 2002-10-01
SK7292002A3 (en) 2002-12-03
CO5271676A1 (es) 2003-04-30
MXPA02004220A (es) 2002-10-17
IL148813A0 (en) 2002-09-12
WO2001032165A1 (en) 2001-05-10
EP1225884A4 (en) 2005-06-15
HK1049105A1 (zh) 2003-05-02
AP2002002446A0 (en) 2002-03-31
US20030212112A1 (en) 2003-11-13
CZ20021443A3 (cs) 2003-01-15
PL355262A1 (en) 2004-04-05
EP1225884A1 (en) 2002-07-31
HUP0203682A2 (hu) 2003-04-28
NO20021937L (no) 2002-05-30
BG106623A (bg) 2003-02-28
AU772909B2 (en) 2004-05-13
NO20021937D0 (no) 2002-04-24
EA200200502A1 (ru) 2002-10-31
HUP0203682A3 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
OA12078A (en) Method for administering a phosphodiesterase 4 inhibitor.
US20060069155A1 (en) Method for reducing exacerbations associated with COPD
JP6174666B2 (ja) ナルトレキソンの徐放型配合物
US6511985B1 (en) Combination of cerivastatin and fibrates
HU202753B (en) Process for producing retard pharmaceutical compositions containing cetotiphene
TWI224013B (en) Controlled release formulation for treating COPD
AU2001279023B2 (en) Method for reducing exacerbations associated with COPD
JPH0141608B2 (no)
AU2001279023A1 (en) Method for reducing exacerbations associated with COPD
Bays Extended-release niacin/lovastatin: the first combination product for dyslipidemia
WO2005123082A1 (fr) Composition anti-hyperlipemie
Kelly et al. Pharmacokinetic properties and clinical efficacy of once-daily sustained-release naproxen
ZA200203349B (en) Method for administering a phosphodiesterase 4 inhibitor.
JP2016514125A (ja) バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
CN115590851B (zh) 4-（4-二乙氨基-1-甲基丁氨基）-7-氯喹啉衍生物在制备治疗肥胖药物中的应用
Awni et al. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine
WO2020053218A1 (en) Treatment of psoriasis
WO2020053219A1 (en) Treatment of psoriasis
AU2004201503A1 (en) Controlled Release Formulation for Treating COPD
MXPA06014463A (es) Composicion farmaceutica que contiene una combinacion de antiespasmodico y analgesico y su uso.